NEWS & EVENTS

Latest news and upcoming events

Ysios Capital ESG Report
20 Nov 2024

Ysios Capital ESG Report

Upcoming events

  • AI in Drug Discovery and Biomedicine
    31 March 2025
    Barcelona

    download

  • Redefining Early Stage of Investment (RESI)
    1 April 2025
    Barcelona

    download

  • Life Sciences Conference – Van Lanschot Kempen
    2 - 3 April 2025
    Amsterdam

    download

  • Swisss Biotech Day
    5 - 6 May 2025
    Basel

    download
01 Apr 2015

Kala Pharmaceuticals Announces Positive Results from Phase 3 Trial of KPI-121 in Cataract Surgery

WALTHAM, Mass., April 1, 2015 -- Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus penetrating particle (MPP) technology, today announced positive top-line results from a Phase 3 clinical trial of KPI-121, its nanoparticle loteprednol etabonate MPP product candidate, for the treatment of inflammation and pain in patients who had undergone cataract surgery.
17 Mar 2015

CVRx® Barostim Therapy™ for Heart Failure Clinical Trial Results Presented in a Featured Clinical Research Session of the American College of Cardiology Annual Conference

Minneapolis – March 17, 2015 – CVRx, Inc., a private medical device company, announced that positive results from the Barostim Therapy for Heartn Failure randomized, controlled clinical trial were presented at American College of Cardiology (ACC) in a Featured Clinical Research Session.
Aura Biosciences Closes $21M Series B Financing<
06 Mar 2015

Aura Biosciences Closes $21M Series B Financing

Aura Biosciences’ platform is based on viral nanoparticles, a new class of drugs that harness the potential of a unique cell targeting for the treatment of cancer. 
24 Feb 2015

Prexton Therapeutics raises €8.7 million ($10 million) in a Series A round

Geneva, Switzerland, February 24 2015 - Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including Parkinson’s disease, today announced the closing of a Series A financing of €8.7 million ($10 million) co-led by Sunstone Capital and Ysios Capital.
02 Feb 2015

CVRx® Barostim Therapy™ for Heart Failure Clinical Trial Results Selected to be Presented in a Featured Clinical Research Session of the American College of Cardiology Annual Conference

Minneapolis – February 2, 2015 – CVRx, Inc., a private medical device company, announced that the results from the Barostim Therapy for Heart Failure randomized, controlled clinical trial have been accepted by the American College of Cardiology (ACC) for presentation in a Featured Clinical Research Session.
22 Jan 2015

European Patent Office issues key patent to TiGenix for expanded adipose-derived stem cell compositions

Leuven (BELGIUM) – 22 January, 2015 –TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that the European Patent Office (EPO) has issued European Patent EP2292736 relating to an adipose-derived stem cell composition.
20 Jan 2015

AM-Pharma starts Adaptive Phase II trial of recAP in Acute Kidney Injury

Bunnik, The Netherlands, 20 January 2015.
22 Dec 2014

TiGenix submits its pivotal US trial design for Cx601 to the FDA for Special Protocol Assessment

Leuven (BELGIUM) – 22 December, 2014 –TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC’s, in inflammatory and autoimmune diseases, announced today that it has submitted to the Food and Drug Administration (FDA) the required documentation for a Special Protocol Assessment (SPA) of its pivotal Phase III trial design for Cx601 in the treatment of complex perianal fistulas in patients with Crohn’s disease in the United States.
10 Dec 2014

TiGenix starts Phase I trial of Cx611 in severe sepsis

Leuven (BELGIUM) – 10 December, 2014 –TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that the first subject has been entered into its Phase I trial of Cx611 in severe sepsis.
13 Nov 2014

AM-Pharma presents preclinical data on mode-of-action for recAP in Acute Kidney Injury at ASN meeting

Bunnik, The Netherlands, 13 November 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, today presents further preclinical data on its drug candidate recAP, at the American Society of Nephrology (ASN) meeting Kidney Week in Philadelphia, PA, USA.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

rabbywallet offers a seamless, secure solution for managing digital assets. With its intuitive design, it ensures fast transactions and robust security for all your cryptocurrency needs.